These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 5121654)

  • 1. Clinical study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in carcinoma of the lung.
    Mizgerd JB; Amick RM; Hilal HM; Patno ME
    Cancer Chemother Rep; 1971 Feb; 55(1):83-6. PubMed ID: 5121654
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
    Kline I; Woodman RJ; Gang M; Venditti JM
    Cancer Chemother Rep; 1971 Feb; 55(1):9-28. PubMed ID: 5121657
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
    Luce JK; Thurman WG; Isaacs BL; Talley RW
    Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
    [No Abstract]   [Full Text] [Related]  

  • 4. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.
    Kingra GS; Comis R; Olson KB; Horton J
    Cancer Chemother Rep; 1971 Jun; 55(3):281-3. PubMed ID: 5115849
    [No Abstract]   [Full Text] [Related]  

  • 5. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
    Stolinsky DC; Bogdon DL; Solomon J; Bateman JR
    Cancer; 1972 Sep; 30(3):654-9. PubMed ID: 5075351
    [No Abstract]   [Full Text] [Related]  

  • 6. 5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy.
    Komp DM; Land VJ; Nitschke R; Cangir A; Dyment P
    Cancer Chemother Rep; 1975; 59(2 Pt 1):371-6. PubMed ID: 1097094
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination chemotherapy with CCNU (NSC-79037) and 5-(3, 3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196).
    Chang H; Freireich EJ; Khaliq A; Einhorn L; Gottlieb JA
    Cancer Chemother Rep; 1975; 59(4):769-71. PubMed ID: 1100230
    [No Abstract]   [Full Text] [Related]  

  • 8. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma.
    Moertel CG; Reitemeier RJ; Hahn RG; Schutt AJ
    Cancer Chemother Rep; 1970 Dec; 54(6):471-3. PubMed ID: 4946016
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Apr; 56(2):267-9. PubMed ID: 5043230
    [No Abstract]   [Full Text] [Related]  

  • 10. Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors.
    Levin VA; Crafts D; Wilson CB; Kabra P; Hansch C; Boldrey E; Enot J; Neely M
    Cancer Chemother Rep; 1975; 59(2 Pt 1):327-31. PubMed ID: 1149010
    [No Abstract]   [Full Text] [Related]  

  • 11. Suppression of experimental allergic encephalomyelitis by NSC 82196, a new imidazole carboxamide derivative.
    Vogel CL; De Vita VT; Lisak RP; Kies MW
    Cancer Res; 1969 Dec; 29(12):2249-53. PubMed ID: 5369677
    [No Abstract]   [Full Text] [Related]  

  • 12. Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.
    Gerner RE; Moore GE
    Cancer Chemother Rep; 1973 Feb; 57(1):83-4. PubMed ID: 4704107
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma.
    Frei E; Luce JK; Talley RW; Vaitkevicius VK; Wilson HE
    Cancer Chemother Rep; 1972 Oct; 56(5):667-70. PubMed ID: 4569060
    [No Abstract]   [Full Text] [Related]  

  • 14. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
    Carter SK; Friedman MA
    Eur J Cancer (1965); 1972 Feb; 8(1):85-92. PubMed ID: 4552317
    [No Abstract]   [Full Text] [Related]  

  • 15. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 16. Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
    Vogel CL; Primack A; Owor R; Kyalwazi SK
    Cancer Chemother Rep; 1973 Feb; 57(1):65-71. PubMed ID: 4704105
    [No Abstract]   [Full Text] [Related]  

  • 17. Improved systemic chemotherapy for malignant melanoma.
    Larsen RR; Hill GJ
    Am J Surg; 1971 Jul; 122(1):36-41. PubMed ID: 5091852
    [No Abstract]   [Full Text] [Related]  

  • 18. 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of advanced acute lymphocytic leukemia in children.
    Finklestein JZ; Albo V; Ertel I; Karon M; Hammond D
    Cancer Chemother Rep; 1972 Aug; 56(4):523-6. PubMed ID: 4507686
    [No Abstract]   [Full Text] [Related]  

  • 19. Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
    Gams RA; Carpenter JT
    Cancer Chemother Rep; 1974; 58(5 Pt 1):753-4. PubMed ID: 4214608
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
    Falkson G; Van der Merwe AM; Falkson HC
    Cancer Chemother Rep; 1972 Oct; 56(5):671-7. PubMed ID: 4569061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.